*Sponsored
Krypton Street Initiates Coverage On Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) Starting This Morning—Monday, June 30, 2025
Here's Why (CVKD) Just Hit Our Watchlist:
Ultra Low Float: (CVKD) Has Less Than 1.5M Shares In The Float Which Could Set The Stage For Amplified Moves If Demand Starts To Shift.
Analyst Coverage: Multiple Analysts Covering (CVKD) Have Issued Targets Between $30 And $45—With The $45 Target Suggesting Over 330% Potential Upside.
Technical Levels Watched: (CVKD) Is Trending Near Its 5, 20, 50, And 100-Day Moving Averages.
Abbott Collaboration Announced: (CVKD) Has Partnered With Abbott For Its Pivotal Phase 3 Trial.
Take A Look At (CVKD) While It's Still Early…
June 30, 2025 Monday's Early Radar: See Why (CVKD) is Topping Our Watchlist Dear Reader, Please tell me you have (CVKD) pulled up this morning. (CVKD) just tapped $12.11 on an approximate 16% early move. 
A rare window is opening this morning. Momentum is coiling, the kind that doesn't wait around, and the signals lining up on our screen have earned this company a spot right at the top of our watchlist. That company is Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)—and it's at the very top of our screen this morning—Monday, June 30, 2025. Keep reading to see why (CVKD) just hit our radar. Aiming to Solve a High-Stakes Medical Challenge
(CVKD) is advancing tecarfarin, a late-stage, reversible anticoagulant designed to help prevent heart attacks and strokes in patients who require chronic anticoagulation—specifically those with LVADs and ESKD + AFib, where safer alternatives are desperately needed. Unlike traditional anticoagulants that carry serious side effects, tecarfarin's unique single-enzyme (CES2) metabolism may reduce drug interactions, dietary complications, and bleeding risks, positioning it as a differentiated contender in this critical space. Why (CVKD) Just Hit The Top Of Our Radar
(CVKD)'s float sits at under 1.5M shares, which could set the stage for big swing potential if demand begins to shift. Analyst's $45 Target Suggests Over 330% Upside Potential…
Multiple analysts are tracking CVKD: - David Bautz, PhD at Zacks SCR, has a $30 valuation.
- Joseph Pantginis at HC Wainwright is at $32, as reported by TipRanks.
- Robert LeBoyer at Noble Capital Markets recently reiterated a $45 target.
With (CVKD) closing at $10.44 on Friday, LeBoyer's $45 target suggests over 330% upside potential. Key technical levels are in focus as (CVKD) hovers near its primary moving averages. - 5-Day MA: 10.75
- 20-Day MA: 13.30
- 50-Day MA: 14.70
- 100-Day MA: 16.38
As we head into Monday, (CVKD) is sitting at the top of our early watchlist.
Backed by Abbott for a Critical Phase 3 Trial
(CVKD) isn't moving alone. It has a collaboration with Abbott, which is providing trial design, site identification, and HeartMate 3™ LVAD expertise for (CVKD)'s pivotal Phase 3 TECH-LVAD trial. Abbott's commitment signals a validation many smaller biotech companies rarely see, aligning Cadrenal's advancement of tecarfarin with a global leader in cardiovascular care. Behind the Scenes: Positioned for the Next Step
(CVKD) has completed the technical transfer of tecarfarin's dr-ug substance to a US-based facility, strengthening supply chain security ahead of its Phase 3 trial, which is anticipated to launch in 2H 2025. After a Type D meeting with the FDA, (CVKD)is finalizing its trial design for submission, positioning tecarfarin for a path that could address critical patient needs. From a fiscal standpoint, the company reported $7.3Min cash as of March 31, 2025, and while additional capital will be needed to advance the trial, (CVKD) is maintaining operational discipline as it prepares for its next phase. 
Recent Developments Fueling This Momentum Potential
June 12, 2025: New Research Highlights LVAD Anticoagulation Burden
(CVKD spotlighted findings from Guidehouse, revealing the clinical and financial strain faced by LVAD patients requiring chronic anticoagulation, with major bleeds averaging $39,000 per event and higher for intracranial cases. Guidehouse identified tecarfarin as a potential alternative to warfarin, noting its single-enzyme (CES2) metabolism could reduce drug interactions and bleeding complications for this high-risk population. CEO Quang X. Pham stated this reinforces the potential for tecarfarin to transform care for patients who currently have no safe alternative. May 19, 2025: Advancing Toward Phase 3 with Abbott
(CVKD announced continued preparations for its Phase 3 TECH-LVAD trial, focused on patients with LVADs requiring chronic anticoagulation. The company's collaboration with Abbott, which provides trial design, site support, and HeartMate 3™ expertise, signals strong industry alignment ahead of the pivotal study. Following a Type D meeting with the FDA in February, Cadrenal is finalizing its study design, with trial initiation targeted for the second half of 2025. May 8, 2025: Financial Results and Operational Progress
(CVKD) reported $7.3M in cash as of March 31, 2025, noting it has completed the technical transfer and cGMP manufacturing of tecarfarin's drug substance to a U.S.-based facility, strengthening its supply chain as it approaches Phase 3 readiness. While (CVKD) has sufficient capital for current operations, the company plans to secure additional funding to support its upcoming clinical milestones. These updates align with the tight float, technical positioning, and analyst targets we are watching closely, reinforcing why (CVKD) is topping our watchlist right now as we head into Monday.
Why We're Watching (CVKD) Right Now
Between the tight float, the upcoming pivotal trial, multiple analyst targets well above current levels, and a critical partnership with Abbott, Cadrenal Therapeutics (CVKD) is positioned to attract significant attention. We'll have all eyes on (CVKD) this morning—monitoring it for any early signals. If you are tracking the biotech landscape for potential movers with potential catalysts and high-level backing, (CVKD) is one to keep at the top of your screen this morning. 7 Reasons Why (CVKD) Is Topping Our Watchlist This
Morning—Monday, June 30, 2025
1. Ultra Low-Float: With less than 1.5M shares in the float, (CVKD) could see the potential for amplified moves if demand begins to shift. 2. Analyst Coverage: Multiple analysts covering (CVKD) have issued targets between $30 and $45—well above its recent close of $10.44—with the $45 target suggesting over 330% potential upside.
3. Technical Levels Aligned: Currently, (CVKD) is trending near its 5, 20, 50, and 100-day moving averages, a situation many watch for potential breakouts. 4. Abbott Collaboration Secured: For its pivotal Phase 3 trial, (CVKD) has partnered with Abbott, aligning with a major player in cardiovascular device leadership. 5. Phase 3 Readiness: Manufacturing for tecarfarin is complete at a US-based facility as (CVKD) prepares for its upcoming Phase 3 trial launch in 2H 2025. 6. High-Impact Research: Recent findings shared by (CVKD) highlight the heavy burden LVAD patients face, underscoring the potential role of tecarfarin. 7. Solid Fiscal Position: As of March 31, 2025, (CVKD) reported $7.3M in cash, providing runway as it advances toward its next set of clinical milestones. 
Momentum has been building around (CVKD) as key signals continue to line up. Analyst targets, technical positioning, and a high-level partnership are now all pointing in the same direction. Now's the time to see why (CVKD) is topping our watchlist this morning—Monday, June 30, 2025. Take A Look At (CVKD) While It's Still Early…
Cadrenal Therapeutics (CVKD) is stepping into the spotlight as a rare window is opening this morning: a tight float, layered analyst coverage, technical signals worth tracking, and the backing of a leading industry player for its upcoming pivotal trial. Its focused progress toward Phase 3 readiness, combined with strong data underscoring the need for tecarfarin, sets the stage for potential attention ahead. We have all eyes on (CVKD) this morning. Take a look at (CVKD) while it's still early. (CVKD) just tapped $12.11 on an approximate 16% early move. Keep your eyes peeled—my next update could be out shortly. Sincerely, Alex Ramsay
Co-Founder / Managing Editor
Krypton Street Newsletter | 
No comments:
Post a Comment